Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib

INTRODUCTION. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases and has led to a longer median overall survival (OS) time and time to progression (TTP) in patients with advanced hepatocellular carcinoma (HCC). This study was conducted to assess the link...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Vincenzi, Bruno, Santini, Daniele, Russo, Antonio, Addeo, Raffaele, Giuliani, Francesco, Montella, Liliana, Rizzo, Sergio, Venditti, Olga, Frezza, Anna Maria, Caraglia, Michele, Colucci, Giuseppe, Del Prete, Salvatore, Tonini, Giuseppe
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2010
Konular:
Hepatobiliary
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3227883/
https://ncbi.nlm.nih.gov/pubmed/20051477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2009-0143
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller